In particular, the study was structured to assess: (1) the acute effects of pasireotide on circulating levels of plasma ACTH after a single 600 μg s.c. injection, and whether this would allow prediction of individual longer-term response, (2) the effects of 4-week of pasireotide s.c. on circulating plasma ACTH, (3) the effects of pasireotide LAR given monthly for 6 months on circulating plasma ACTH, and (4) the effect of pasireotide s.c. and LAR on tumor volume. The gene discussed is POMC; the disease is neoplasm.